Department of Health and Human Services June 6, 2007 – Federal Register Recent Federal Regulation Documents
Results 1 - 15 of 15
Determination of Regulatory Review Period for Purposes of Patent Extension; RAPLON
The Food and Drug Administration (FDA) has determined the regulatory review period for RAPLON and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.
Implantation or Injectable Dosage Form New Animal Drugs; Spectinomycin Sulfate
The Food and Drug Administration (FDA) is amending the animal drug regulations to reflect approval of a supplemental new animal drug application (NADA) filed by Pharmacia & Upjohn Co., a Div. of Pfizer, Inc. The supplemental NADA provides for revising nomenclature for two bovine respiratory pathogens on labeling for spectinomycin sulfate injectable solution.
This site is protected by reCAPTCHA and the Google
Privacy Policy and
Terms of Service apply.